title: MR and GR functional SNPs may modulate tobacco smoking susceptibility.
abstract: A number of studies have demonstrated that stress is involved in all aspects of smoking behavior, including initiation, maintenance and relapse. The mineralocorticoid (MR) and glucocorticoid (GR) receptors are expressed in several brain areas and play a key role in negative feedback of the hypothalamic-pituitary-adrenal (HPA) axis. As nicotine increases the activation of the HPA axis, we wondered if functional SNPs (single nucleotide polymorphisms) in MR and GR coding genes (NR3C2 rs5522 and NR3C1 rs6198, respectively) may be involved in smoking susceptibility. The sample included 627 volunteers, of which 514 were never-smokers and 113 lifetime smokers. We report an interaction effect between rs5522 and rs6198 SNPs. The odds ratio (OR) for the presence of the NR3C2 rs5522 Val allele in NR3C1 rs6198 G carriers was 0.18 (P = 0.007), while in rs6198 G noncarriers the OR was 1.83 (P = 0.027). We also found main effects of the NR3C1 rs6198 G allele on number of cigarettes smoked per day (P = 0.027) and in total score of the Fagerström Test for Nicotine Dependence (P = 0.007). These findings are consistent with a possible link between NR3C2 and NR3C1 polymorphisms and smoking behavior and provide a first partial replication for a nominally significant GWAS finding between NR3C2 and tobacco smoking.
authors.affiliation: Department of Genetics, Instituto de Biociências, Universidade Federal do Rio Grande do Sul, Avenida Bento Gonçalves - 15053, Porto Alegre, RS, 91501-970, Brazil.
authors.forename: Diego L
authors.initials: DL
authors.lastname: Rovaris
authors.forename: Nina R
authors.initials: NR
authors.lastname: Mota
authors.forename: Lucas A
authors.initials: LA
authors.lastname: de Azeredo
authors.forename: Renata B
authors.initials: RB
authors.lastname: Cupertino
authors.forename: Guilherme P
authors.initials: GP
authors.lastname: Bertuzzi
authors.forename: Evelise R
authors.initials: ER
authors.lastname: Polina
authors.forename: Verônica
authors.initials: V
authors.lastname: Contini
authors.forename: Gustavo L
authors.initials: GL
authors.lastname: Kortmann
authors.forename: Eduardo S
authors.initials: ES
authors.lastname: Vitola
authors.forename: Eugenio H
authors.initials: EH
authors.lastname: Grevet
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Grassi-Oliveira
authors.forename: Sidia M
authors.initials: SM
authors.lastname: Callegari-Jacques
authors.forename: Claiton H D
authors.initials: CH
authors.lastname: Bau
mesh_terms: D000328:Adult; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008297:Male; D020641:Polymorphism, Single Nucleotide; D011965:Receptors, Glucocorticoid / Q000235:genetics*; D018161:Receptors, Mineralocorticoid / Q000235:genetics*; D012907:Smoking / Q000235:genetics*
chemical_list: C497713:NR3C1 protein, human; C561839:NR3C2 protein, human; D011965:Receptors, Glucocorticoid; D018161:Receptors, Mineralocorticoid
references.citation: Biol Psychol. 2011 Sep;88(1):1-12
references.pmid: 21741435
references.citation: Tob Control. 2004 Sep;13(3):251-7
references.pmid: 15333880
references.citation: J Rheumatol. 2001 Nov;28(11):2383-8
references.pmid: 11708406
references.citation: J Steroid Biochem Mol Biol. 1997 Jan;60(1-2):43-50
references.pmid: 9182857
references.citation: Addiction. 2005 Sep;100(9):1330-9
references.pmid: 16128722
references.citation: Neuropsychopharmacology. 2007 Nov;32(11):2310-20
references.pmid: 17342167
references.citation: Neuropsychopharmacology. 2008 Mar;33(4):749-60
references.pmid: 17507912
references.citation: Psychol Med. 2006 Feb;36(2):167-79
references.pmid: 16420713
references.citation: J Biol Chem. 2011 Feb 4;286(5):3177-84
references.pmid: 21149445
references.citation: Neurosci Biobehav Rev. 2010 May;34(6):853-66
references.pmid: 19631685
references.citation: Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12480-4
references.pmid: 8618925
references.citation: Behav Genet. 2011 Mar;41(2):253-61
references.pmid: 20680430
references.citation: Biol Psychiatry. 2008 Jun 1;63(11):1061-5
references.pmid: 17976537
references.citation: Psychoneuroendocrinology. 2011 May;36(4):484-94
references.pmid: 20884124
references.citation: Mol Cell Biol. 2001 Feb;21(3):781-93
references.pmid: 11154266
references.citation: Ann N Y Acad Sci. 2008 Oct;1141:105-30
references.pmid: 18991954
references.citation: Genes Brain Behav. 2010 Aug;9(6):658-67
references.pmid: 20528958
references.citation: Trends Neurosci. 2008 Jan;31(1):1-7
references.pmid: 18063498
references.citation: Bipolar Disord. 2009 Feb;11(1):95-101
references.pmid: 19133972
references.citation: Psychopharmacology (Berl). 1992;106(2):275-81
references.pmid: 1347955
references.citation: J Clin Endocrinol Metab. 2006 Dec;91(12):5083-9
references.pmid: 17018659
references.citation: J Neurochem. 2012 Mar;120(6):1108-16
references.pmid: 22191943
references.citation: Neuroimmunomodulation. 2009;16(5):340-52
references.pmid: 19571595
references.citation: Eur Arch Psychiatry Clin Neurosci. 2013 Apr;263(3):181-8
references.pmid: 22584804
references.citation: Biol Psychiatry. 2007 Oct 15;62(8):863-9
references.pmid: 17716631
references.citation: Drug Alcohol Depend. 2000 May 1;59 Suppl 1:S61-81
references.pmid: 10773438
references.citation: J Affect Disord. 2011 Nov;134(1-3):138-44
references.pmid: 21764460
references.citation: J Clin Psychopharmacol. 2012 Dec;32(6):820-3
references.pmid: 23131881
references.citation: Mol Psychiatry. 2008 Apr;13(4):368-73
references.pmid: 18227835
references.citation: Psychol Med. 2005 Feb;35(2):245-56
references.pmid: 15841682
references.citation: J Psychiatr Res. 2012 Apr;46(4):436-43
references.pmid: 22277304
references.citation: Drug Alcohol Depend. 2009 Apr 1;101(1-2):128-31
references.pmid: 19111403
references.citation: Neuron. 1994 Dec;13(6):1457-62
references.pmid: 7993637
references.citation: Psychoneuroendocrinology. 2011 Jun;36(5):699-709
references.pmid: 21095064
references.citation: Nicotine Tob Res. 2011 Sep;13(9):809-19
references.pmid: 21543549
references.citation: Int J Psychophysiol. 2006 Mar;59(3):228-35
references.pmid: 16337291
references.citation: Health Psychol. 2002 Mar;21(2):122-30
references.pmid: 11950102
references.citation: Biol Psychol. 2008 Oct;79(2):179-84
references.pmid: 18502562
references.citation: J Psychiatr Res. 2011 Jun;45(6):829-34
references.pmid: 21092985
references.citation: Neuropsychopharmacology. 2005 Apr;30(4):821-32
references.pmid: 15702139
references.citation: Psychoneuroendocrinology. 2010 Apr;35(3):339-49
references.pmid: 19665310
references.citation: Life Sci. 1992;50(6):435-42
references.pmid: 1734161
references.citation: Psychopharmacology (Berl). 1982;78(4):305-8
references.pmid: 6818588
references.citation: Nucleic Acids Res. 1991 Oct 11;19(19):5444
references.pmid: 1681511
references.citation: Brain Res Rev. 2008 Nov;59(1):164-84
references.pmid: 18675846
references.citation: Nicotine Tob Res. 2008 May;10(5):843-50
references.pmid: 18569758
references.citation: Addict Biol. 2007 Mar;12(1):93-9
references.pmid: 17407502
references.citation: Addict Biol. 2009 Jul;14(3):349-55
references.pmid: 19413563
references.citation: Neuropsychopharmacology. 2007 Jun;32(6):1295-301
references.pmid: 17133261
references.citation: Hum Genet. 2003 Jan;112(1):91-7
references.pmid: 12483305
references.citation: J Clin Pharmacol. 1977 Jul;17(7):389-97
references.pmid: 881471
references.citation: Neurosci Biobehav Rev. 2012 May;36(5):1418-41
references.pmid: 22405889
references.citation: Neuromolecular Med. 2013 Mar;15(1):122-32
references.pmid: 23055001
references.citation: Psychopharmacology (Berl). 2005 Aug;181(1):107-17
references.pmid: 15834539
references.citation: Neuropsychopharmacology. 2005 Sep;30(9):1751-63
references.pmid: 15870834
references.citation: Psychoneuroendocrinology. 2011 Nov;36(10):1460-9
references.pmid: 21531081
references.citation: Arch Gen Psychiatry. 2005 Oct;62(10):1142-7
references.pmid: 16203959